← Human Trials & Peer-Reviewed Studies
Effects of peripheral administration of synthetic human glucose-dependent insulinotropic peptide (GIP) on energy expenditure and subjective appetite sensations in healthy normal weight subjects and obese patients with type 2 diabetes
Plain-language guide to PMID 19178509 (2009): randomized and placebo-controlled clinical trial study of GIP (Gastric Inhibitory Polypeptide).
Key Facts
- PMID
- 19178509
- Journal
- Clinical endocrinology
- Year
- 2009
- Study type
- Clinical Trial
- Authors
- Daousi C et al. (7 authors)
- DOI
- 10.1111/j.1365-2265.2008.03451.x
What This Study Did, in Plain Language
What Was Tested
Researchers studied GIP (Gastric Inhibitory Polypeptide) in this clinical trial publication.
Apart from their role in insulin secretion and glucose homeostasis, the incretin hormones glucagon-like peptide-1 (GLP-1) and glucose-dependent insulinotropic peptide (GIP) exert a number of extra-pancreatic effects which in the case of GIP remain largely unknown.
Who Took Part
The age groups tagged for this paper are adults and middle-aged adults, men only.
Energy expenditure (EE) was measured throughout with indirect calorimetry and subjects were given a series of visual analogue scales to rate hourly their hunger, fullness, urge to eat and prospective consumption of food.
Immediately following termination of the infusions all subjects were offered a free choice buffet lunch and total calorie and macronutrient intake was calculated.
How the Study Was Run
The researchers set it up as a randomized and placebo-controlled study.
The participants were allocated by chance, so the GIP (Gastric Inhibitory Polypeptide) group and the comparison group should start out alike.
A placebo (an inactive look-alike) gave the GIP (Gastric Inhibitory Polypeptide) group a baseline to be compared against.
What Was Measured
PubMed files the paper under topics including Administration, Topical, Appetite, Case-Control Studies, Diabetes Mellitus, Type 2, Energy Metabolism, Gastric Inhibitory Polypeptide and Taste.
What This Means in Plain Language
The paper is a randomized and placebo-controlled study of GIP (Gastric Inhibitory Polypeptide).
The abstract goes on to report its results in about 4 sentences; this page does not restate them, so read the paper for the findings and their limits.
The publication is from 2009 (Clinical endocrinology), a journal based in England.
More context: the GIP (Gastric Inhibitory Polypeptide) compound page, all human trials.
Our Notes on the Compound
GIP (Gastric Inhibitory Polypeptide): A 42-amino-acid gut hormone that boosts insulin release after meals; one of the two receptors tirzepatide acts on.
Related Pages
Source: PubMed record. This explanation is written by PeptideWhiz from the public record. For research and education only. Not medical advice; no dosing information is given.